PRDX6抗体

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 60 μg, Lane 1-4: Hela cells, mouse intestinum tenue tissue, 293T cells, 231 cells, Primary antibody: P07560(PRDX6 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 second    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P07560(PRDX6 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P07560(PRDX6 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

Peroxiredoxin 6 (PRDX6) is a unique member of the peroxiredoxin family, a class of antioxidant enzymes that play critical roles in cellular defense against oxidative stress by reducing reactive oxygen species (ROS) like hydrogen peroxide and lipid peroxides. Unlike other peroxiredoxins, PRDX6 possesses both glutathione peroxidase and calcium-independent phospholipase A2 (iPLA2) activities, enabling its dual function in redox regulation and phospholipid metabolism. It is widely expressed in tissues, particularly in the lungs, liver, and kidneys, and is implicated in cellular processes such as inflammation, apoptosis, and membrane repair.

PRDX6 antibodies are essential tools for studying the protein's expression, localization, and functional roles in health and disease. These antibodies are commonly used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate PRDX6's involvement in oxidative stress-related pathologies, including cancer, neurodegenerative disorders, and lung injury. Researchers also utilize PRDX6 antibodies to explore its interaction with signaling pathways, such as NF-κB and MAPK, which are linked to inflammation and stress responses. Additionally, the antibodies aid in evaluating PRDX6's potential as a therapeutic target or biomarker in conditions like acute respiratory distress syndrome (ARDS) or ischemic-reperfusion injury. Validation of PRDX6 antibodies typically involves knockout controls or siRNA-based silencing to ensure specificity, given the protein's structural similarities to other peroxiredoxins. Commercially available antibodies often target conserved epitopes across species, enabling cross-reactivity in human, mouse, and rat models.